Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539297 | 0.98 | LTA4H (0.42) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL6538486 | 0.87 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL27396397 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042470 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042429 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28106834 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042226 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042424 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042428 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA | |
| SCHEMBL28042227 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720421-B2 | STORAGE STABILITY: GOOD RAW-STOCK STORABILITY BEFORE RECORDING AND GOOD IMAGE STORABILITY AFTER RECORDING | FUJI PHOTO FILM CO., LTD. (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030166961-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | FUJI PHOTO FILM CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| US-20020161225-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | FUJI PHOTO FILM CO., LTD. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166961-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | UROD, ATIC, DDC | NPC1 3790/4885RAB9A 3725/4885SMN1; SMN2 1869/4885 |
| US-20020161225-A1 | Phenylurethane compounds and methods for producing same, asymmetric urea compounds and methods for producing same, barbituric acid derivative, and diazo thermal recording material containing the derivative | UROD, ATIC, DDC | NPC1 3790/4885RAB9A 3725/4885SMN1; SMN2 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.